Pharmaceuticals
US6949577B2 · kind B2 · utility
5Cited by
2References
24Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 17, 2003 |
| Grant date | Sep 27, 2005 |
| Priority date | — |
| Expiry date | Mar 17, 2023 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D403/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides compounds of formula (I) as well as the use of such compounds in pharmaceutical compositions and methods of treatment.The compounds described herein represent a class of TAFIa inhibitors suitable for use in treating conditions such as thrombosis, atherosclerosis, adhesions, dermal scarring, cancer, fibrotic conditions, inflammatory diseases and those conditions which benefit from maintaining or enhancing bradykinin levels in the body.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.